Jagsonpal Pharmaceuticals (JAGSNPHARM) investor relations material

Executive summary

• Leadership team strengthened with new COO and CFO, focusing on long-term growth and operational excellence.

• Unaudited financial results for the quarter and nine months ended 31 December 2025 were approved by the Board of Directors on 21 January 2026.

• Q3 performance was flat, below expectations, attributed to market headwinds and internal strategic recalibration.

• Nine-month period showed resilience with 6% revenue growth and 12.5% bottom line improvement year-over-year.

• Strong liquidity position maintained, with cash balances rising by ₹152 Mn in Q3 to ₹1,757 Mn.

Financial highlights

• Q3 revenue at ₹729.45 million; EBITDA at ₹166 million with a margin of 22.7%.

• Q3 PAT grew 10% year-over-year to ₹125 million; PAT margin improved by 160 bps to 17.1%.

• Nine-month revenue up 6% year-over-year to ₹2,230 million; EBITDA up 5% to ₹503 million; PAT up 12.5% to ₹359 million.

• Free cash balance increased to ₹1,757 million, up by ₹152 million in the quarter.

• Net profit for the quarter was ₹109.51 million, compared to ₹125.74 million in the same quarter last year.

Outlook and guidance

• Expecting double-digit growth from Q4 onwards, aiming for 12%-14% organic growth over the next 3-4 years barring macro changes.

• Growth drivers include price increases, new product launches, and volume growth, with a focus on high-potential brands.

• Growth initiatives are expected to reflect in performance from Q4FY26, with confidence in stronger growth ahead.

• Targeting field force productivity improvements and expansion in core therapeutic areas.